Garrett C Lowe1, Alexandra Saavedra1, Kurtis B Reed1, Ana I Velazquez2, Roxana S Dronca2, Svetomir N Markovic3, Christine M Lohse4, Jerry D Brewer5. 1. Department of Dermatology, Mayo Clinic, Rochester, MN. 2. Division of Medical Oncology, Mayo Clinic, Rochester, MN. 3. Division of Medical Oncology, Mayo Clinic, Rochester, MN; Division of Hematology, Mayo Clinic, Rochester, MN; Division of Clinical Immunology and Immunotherapeutics, Mayo Clinic, Rochester, MN. 4. Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN. 5. Department of Dermatology, Mayo Clinic, Rochester, MN. Electronic address: brewer.jerry@mayo.edu.
Abstract
OBJECTIVE: To identify changes in the incidence of cutaneous melanoma over time in the fastest-growing segment of the US population-middle-aged adults. PATIENTS AND METHODS: By using the Rochester Epidemiology Project resource, we identified patients aged 40 to 60 years who had a first lifetime diagnosis of melanoma between January 1, 1970, and December 31, 2009, in Olmsted County, Minnesota. The incidence of melanoma and overall and disease-specific survival rates were compared by age, sex, year of diagnosis, and stage of disease. RESULTS: Between 1970 and 2009, age- and sex-adjusted incidence increased significantly over time (P<.001) from 7.9 to 60.0 per 100,000 person-years, with a 24-fold increase in women and a 4.5-fold increase in men. Although not significant (P=.06), the incidence of melanoma increased with age. Overall and disease-specific survival improved over time, with hazard ratios of 0.94 (P<.001) and 0.93 (P<.001) for each 1-year increase in the year of diagnosis, respectively. Each 1-year increase in the age at diagnosis was associated with an increased risk of death from any cause (hazard ratio, 1.07; P=.01) but was not significantly associated with disease-specific death (P=.98). Sex was not significantly associated with death from any cause (P=.81) or death from disease (P=.23). No patient with malignant melanoma in situ died from disease. Patients with stage II, III, and IV disease were more than 14 times more likely to die from disease than were patients with stage 0 or I disease (P<.001). CONCLUSION: The incidence of cutaneous melanoma among middle-aged adults increased over the past 4 decades, especially in middle-aged women, whereas mortality decreased.
OBJECTIVE: To identify changes in the incidence of cutaneous melanoma over time in the fastest-growing segment of the US population-middle-aged adults. PATIENTS AND METHODS: By using the Rochester Epidemiology Project resource, we identified patients aged 40 to 60 years who had a first lifetime diagnosis of melanoma between January 1, 1970, and December 31, 2009, in Olmsted County, Minnesota. The incidence of melanoma and overall and disease-specific survival rates were compared by age, sex, year of diagnosis, and stage of disease. RESULTS: Between 1970 and 2009, age- and sex-adjusted incidence increased significantly over time (P<.001) from 7.9 to 60.0 per 100,000 person-years, with a 24-fold increase in women and a 4.5-fold increase in men. Although not significant (P=.06), the incidence of melanoma increased with age. Overall and disease-specific survival improved over time, with hazard ratios of 0.94 (P<.001) and 0.93 (P<.001) for each 1-year increase in the year of diagnosis, respectively. Each 1-year increase in the age at diagnosis was associated with an increased risk of death from any cause (hazard ratio, 1.07; P=.01) but was not significantly associated with disease-specific death (P=.98). Sex was not significantly associated with death from any cause (P=.81) or death from disease (P=.23). No patient with malignant melanoma in situ died from disease. Patients with stage II, III, and IV disease were more than 14 times more likely to die from disease than were patients with stage 0 or I disease (P<.001). CONCLUSION: The incidence of cutaneous melanoma among middle-aged adults increased over the past 4 decades, especially in middle-aged women, whereas mortality decreased.
Authors: Limin X Clegg; Eric J Feuer; Douglas N Midthune; Michael P Fay; Benjamin F Hankey Journal: J Natl Cancer Inst Date: 2002-10-16 Impact factor: 13.506
Authors: H Irene Hall; Patricia Jamison; John P Fulton; Gayle Clutter; Steven Roffers; Pam Parrish Journal: J Am Acad Dermatol Date: 2003-10 Impact factor: 11.527
Authors: Rona M MacKie; Caroline A Bray; David J Hole; Arthur Morris; Marianne Nicolson; Alan Evans; Valerie Doherty; James Vestey Journal: Lancet Date: 2002-08-24 Impact factor: 79.321
Authors: Lindsay Hollander; Xiaojia Guo; Heino Velazquez; John Chang; Robert Safirstein; Harriet Kluger; Charles Cha; Gary V Desir Journal: Cancer Res Date: 2016-05-09 Impact factor: 12.701